Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Talphera, Inc. (TLPH)
:TLPH
TLPH Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.50 - $1.50
Previous CloseN/A
Volume42.81K
Average Volume (3M)76.31K
Market Cap
$10.42M
Enterprise Value$17.86M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.22
Next Earnings
Mar 06, 2025EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.68
Shares Outstanding17,029,219
10 Day Avg. Volume44,666
30 Day Avg. Volume76,315
Standard Deviation0.24
R-Squared0.00408
Alpha-0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)37.09
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market Cap1.71
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.65
Enterprise Value/Ebitda-1.18
Forecast
1Y Price Target
$5.00Price Target Upside646.27% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Talphera News
PremiumCompany Announcements
Talphera Reports Q3 2024 Results and Study Progress
PremiumCompany Announcements
Talphera Announces CMO Retirement and Successor Appointment
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ExpansionTalphera is expanding the number of clinical sites to 14, from 10, to help expedite the study.
Regulatory ProgressThe FDA agreed to review the PAS submission within 30 days of its submission to enable formal amendments to the study protocol.
Bears Say
Trial RisksKey risks to the rating and price target include failed or equivocal trial results and failure to secure FDA approval for Niyad.
---
Ownership Overview
13.81% Insiders
2.30% Mutual Funds
19.47% Other Institutional Investors
63.00% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
TLPH FAQ
What was Talphera, Inc.’s price range in the past 12 months?
Talphera, Inc. lowest stock price was $0.50 and its highest was $1.50 in the past 12 months.
What is Talphera, Inc.’s market cap?
Talphera, Inc.’s market cap is $10.42M.
When is Talphera, Inc.’s upcoming earnings report date?
Talphera, Inc.’s upcoming earnings report date is Mar 06, 2025 which is in 12 days.
How were Talphera, Inc.’s earnings last quarter?
Talphera, Inc. released its earnings results on Nov 13, 2024. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.19 by $0.06.
Is Talphera, Inc. overvalued?
According to Wall Street analysts Talphera, Inc.’s price is currently Undervalued.
Does Talphera, Inc. pay dividends?
Talphera, Inc. does not currently pay dividends.
What is Talphera, Inc.’s EPS estimate?
Talphera, Inc.’s EPS estimate is -0.17.
How many shares outstanding does Talphera, Inc. have?
Talphera, Inc. has 17,029,219 shares outstanding.
What happened to Talphera, Inc.’s price movement after its last earnings report?
Talphera, Inc. reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.19. Following the earnings report the stock price went down -25.843%.
Which hedge fund is a major shareholder of Talphera, Inc.?
Currently, no hedge funds are holding shares in TLPH
---
Company Description
Talphera, Inc.
AcelRx Pharmaceuticals, Inc. engages in the development and commercialization of therapies use in medically supervised settings. Its products include sufentanil, DZUVEO, DSUVIA ZALVISO US and ZALVISO EU. The company was founded by Thomas A. Schreck and Pamela Pierce Palmer on July 13, 2005 and is headquartered in Redwood City, CA.
---
TLPH Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call revealed positive progress in clinical trials, regulatory advantages, and strong investor support, but also highlighted challenges in patient enrollment and financial constraints that require additional capital.Read More>---
TLPH Stock 12 Month Forecast
Average Price Target
$5.00
▲(646.27% Upside)
Technical Analysis
Galectin Therapeutics
―
Neuronetics
―
Anixa Biosciences
―
Rhythm Pharmaceuticals
―
Alnylam Pharma
―
Best Analysts Covering TLPH
1 Year
1 Year Success Rate
5/15 ratings generated profit
1 Year Average Return
-12.28%
reiterated a buy rating last month
Copying Ed Arce's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -12.28% per trade.
---